Lauren's questions to 10X Genomics Inc (TXG) leadership • Q2 2025
Question
Lauren asked about the discounting on Chromium instruments, questioning if this strategy would continue and how pricing is expected to evolve.
Answer
CEO Serge Saxonov confirmed that the discounting is a direct response to the challenging CapEx environment, allowing them to work creatively with customers who face new spending restrictions. He expects this accretive strategy, which often includes reagent commitments, to continue as long as the current market conditions persist.